Actinium Pharmaceuticals
ATNM
59 hedge funds and large institutions have $29.8M invested in Actinium Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 6 closing their positions.
49% more call options, than puts
Call options by funds: $535K | Put options by funds: $359K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 58 → 59 (+1)
0.03% more ownership
Funds ownership: 21.34% → 21.37% (+0.03%)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
13% less capital invested
Capital invested by funds: $34.1M → $29.8M (-$4.36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$777K |
| 2 |
Barclays
London,
United Kingdom
|
+$170K |
| 3 |
Jane Street
New York
|
+$153K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$140K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$376K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$189K |
| 3 |
Goldman Sachs
New York
|
-$159K |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$149K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$114K |
ATNM Hedge Fund Activity: Q4 2023 in Review
59 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2023, worth a combined $29.8M — down 13% from $34.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATNM positions and 6 closed out — a net gain of 1 holder — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $777K. The largest seller was BlackRock, cutting an estimated $376K.
- 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2023, up from 58 in Q3 2023.
- Funds reported $29.8M of Actinium Pharmaceuticals stock for Q4 2023, down 13% quarter-over-quarter.
- 7 funds opened new Actinium Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
- The largest Actinium Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $777K added.
- The largest Actinium Pharmaceuticals seller in Q4 2023 was BlackRock, an estimated $376K sold.
Based on aggregated 13F filings for Q4 2023.